Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study

Alzheimer Disease Biomarker Testing in Cerebrospinal Fluid: A Method to Harmonize Assay Platforms in the Absence of an Absolute Reference Standard

(2013) H. M. Vanderstichele et al.   CLINICAL CHEMISTRY

Exacerbated CSF abnormalities in younger patients with Alzheimer's disease

(2013) Julien Dumurgier et al.   NEUROBIOLOGY OF DISEASE

Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline

(2012) Michael Grundman et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting

(2012) Julien Dumurgier et al.   Alzheimers & Dementia

Quantifying the Added Value of a Diagnostic Test or Marker

(2012) K. G. M. Moons et al.   CLINICAL CHEMISTRY

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

(2011) N. S. M. Schoonenboom et al.   NEUROLOGY

Indications, réalisation et faisabilité de la ponction lombaire dans 18 centres mémoires de ressources et de recherche

(2011) C. Paquet et al.   REVUE NEUROLOGIQUE

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses

(2010) Hans Brunnström et al.   Alzheimers & Dementia

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic

(2010) Maartje I. Kester et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

(2009) Tero Tapiola et al.   ARCHIVES OF NEUROLOGY

Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

(2009) R. C. Petersen et al.   NEUROLOGY

The primary care diagnosis of dementia in Europe: An analysis using multidisciplinary, multinational expert groups

(2008) J. De Lepeleire et al.   AGING & MENTAL HEALTH

Clinical Criteria for the Diagnosis of Alzheimer Disease: Still Good After All These Years

(2008) Najeeb A. Ranginwala et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

CSF biomarkers in frontotemporal lobar degeneration with known pathology

(2008) H. Bian et al.   NEUROLOGY